Stay updated on Ixazomib Combo in Relapsed/Refractory MM Clinical Trial

Sign up to get notified when there's something new on the Ixazomib Combo in Relapsed/Refractory MM Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ixazomib Combo in Relapsed/Refractory MM Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    A site-wide NIH notice about terminology changes appears, and the site revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.7%
    Check dated 2026-10-20T18:58:44.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The site footer now identifies the platform as revision v3.7.1 instead of v3.7.0.
    Difference
    0.1%
    Check dated 2026-10-06T19:27:14.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    A new revision entry v3.7.0 was added to the study record history. The previous v3.6.6 entry was removed, updating the documented version history.
    Difference
    0.1%
    Check dated 2026-09-15T20:55:24.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    A new revision entry (v3.6.6) appears in the study record history with updated status notes (e.g., Returned, Quality Control Review Has Not Concluded) and the addition of sections like Adverse Events, Outcome Measures (Results), and Participant Flow; the prior revision (v3.6.5) is removed from the history.
    Difference
    0.9%
    Check dated 2026-09-01T18:27:10.000Z thumbnail image
  7. Check
    82 days ago
    Change Detected
    Summary
    New latest revision v3.6.5 appears in the history, replacing the previous v3.6.4 and signaling an administrative update to the record.
    Difference
    0.1%
    Check dated 2026-08-11T08:25:19.000Z thumbnail image
  8. Check
    89 days ago
    Change Detected
    Summary
    Added entries indicate the study record now includes Adverse Events, Baseline Characteristics, Participant Flow, and Outcome Measures (Results), along with the Study Status. The entry also notes that the submission was returned on 2026-07-29 with Quality Control Review not concluded.
    Difference
    0.9%
    Check dated 2026-08-04T08:35:55.000Z thumbnail image

Stay in the know with updates to Ixazomib Combo in Relapsed/Refractory MM Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ixazomib Combo in Relapsed/Refractory MM Clinical Trial page.